Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 8/20 | 0.43 |
| ▸ | CTSL | P07711 | 4/20 | 0.39 |
| ▸ | CTSS | P25774 | 3/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | STK17B | O94768 | 1/20 | 0.35 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25949412 | 0.86 | AAK1 (0.41) | AAK1CTSLCTSSCTSKCTSB | |
| SCHEMBL2722859 | 0.85 | STK17B (0.51) | AAK1CTSLCTSSCTSKCTSB | |
| SCHEMBL2724468 | 0.85 | STK17B (0.51) | AAK1CTSLCTSSCTSKCTSB | |
| SCHEMBL2722858 | 0.85 | STK17B (0.51) | AAK1CTSLCTSSCTSKCTSB | |
| SCHEMBL29437364 | 0.85 | STK17B (0.51) | AAK1CTSLCTSSCTSKCTSB | |
| SCHEMBL25949590 | 0.79 | AAK1 (0.36) | AAK1CTSLCTSSCTSKCTSB | |
| SCHEMBL25950420 | 0.77 | LATS1 (0.45) | AAK1CTSLCTSSCTSKSYK | |
| SCHEMBL8200759 | 0.74 | MAPKAPK2 (0.38) | AAK1CTSSCTSKSYKSTK17B | |
| SCHEMBL14923599 | 0.73 | AAK1 (0.44) | AAK1CTSLCTSSCTSKCTSB | |
| SCHEMBL3356984 | 0.73 | AAK1 (0.44) | AAK1CTSLCTSSCTSKCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230248733-A1 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230248733-A1 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | MKI67, PCNA, HRAS | AAK1 3659/4885CTSL 1154/4885CTSS 1268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.